Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma
Open Access
- 1 November 2007
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 15 (11), 2044-2050
- https://doi.org/10.1038/sj.mt.6300290
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Antibody and CD8+ T Cell Responses against HER2/neu Required for Tumor Eradication after DNA Immunization with a Flt-3 Ligand Fusion VaccineClinical Cancer Research, 2007
- Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical CenterVaccine, 2006
- Optimization of a self antigen for presentation of multiple epitopes in cancer immunityJCI Insight, 2006
- Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanomaCancer, 2005
- Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon ParticlesClinical Cancer Research, 2005
- Understanding the generation and function of memory T cell subsetsCurrent Opinion in Immunology, 2005
- Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccinationInternational Journal of Cancer, 2005
- A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humansJournal of General Virology, 2004
- Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cellsNature Immunology, 2003
- Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells.The Journal of Experimental Medicine, 1987